Biosergen secures fully covered US$4.82M rights issue for antifungal pipeline
What's the deal? BiosergenDealroom has a profile for this one. Try Dealroom →, a Swedish biotech developing antifungal treatments, has completed a fully covered rights issue of 79.84 million shares at US$0.06 each, raising US$4.83M.
The capital will fund clinical development of BSG005, its lead drug candidate for life-threatening fungal infections in immunocompromised patients.
Why now? BSG005 is in Phase I trials and has shown a favourable safety profile in early studies. The fresh capital pushes Biosergen towards potential market entry between 2026 and 2027.
The company last raised US$5.1M in October 2022 to advance the same study.
What could go wrong? Phase I is early, and many drug candidates fail before reaching the market. Biosergen also depends on its development partner, India's Alkem LaboratoriesDealroom has a profile for this one. Try Dealroom →, to move the programme forward.
The signal: As an early-stage biotech, Biosergen is leaning on incremental rights issues — this US$4.82M raise follows US$5.1M secured in October 2022 — to bridge the long, capital-intensive path of antifungal drug development. With BSG005, a variant of nystatin engineered for improved properties, the company is betting that orphan drug designation and a serious unmet need can offset the inherent risks of staying in Phase I more than three years on.
Read more: AInvest
Image credit: theglobalpanorama
